Healthcare
JCR Pharmaceuticals Co., Ltd.(JCRRF)
Live Price
Offline$3.15
+0.00% today
1Y Change
-16.80%
Window
Jun 26, 2025 โ Jun 19, 2026
- Market Cap
- $66.24B
- Revenue Growth
- -22.9%
- EPS Growth
- -187.1%
- Dividend Yield
- 3.7%
Coverage: 252 bars ยท Jun 26, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
JCR Pharmaceuticals Co., Ltd. (JCRRF) is a Healthcare stock with a market cap of $66.24B and listed on OTC. The stock last traded around $3.15 and down 16.8% across the available one-year price window (Jun 26, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of -22.9%, EPS growth of -187.1%, a dividend yield of 3.7%. What stands out right now is revenue -22.9%, EPS -187.1%, free cash flow -313.0% with operating margin -15.0% and ROIC -4.1%. The dividend matters to the case here, with a current yield around 3.7%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines JCRRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-22.9% vs +7.6% peer median
Operating Margin
Below sector median
-15.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 13, 2026 with an EPS surprise of +153.9% and a revenue surprise of +8.7%.
The operating picture looks softer than before
Revenue is at -22.9% and EPS is at -187.1%, with operating margin around -15.0%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 29, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | +153.9% | +0.0% | +0.0% | -24.6% |
2026 Jan 28, 2026 | +125.2% | +0.0% | -12.2% | -12.2% |
2025 Oct 30, 2025 | -9.2% | +0.0% | +0.0% | +0.0% |
Benchmark Edge
JCRRF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
JCRRF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
JCRRF Max Drawdown
-37.10%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for JCRRF and SPY.
Company Overview
JCR Pharmaceuticals Co., Ltd.
Other OTC
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
- Leadership
- Toru Ashida
- IPO Date
- Jan 29, 2021
- Employees
- 934
- Street Address
- 3-19 Kasuga-cho
- Mailing
- Ashiya, 659-0021
- Region
- Ashiya, JP
- Reporting Currency
- USD
- Investor Line
- 81 7 9732 8591
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.8
- Price/Book
- 1.4
Growth
- Revenue
- -22.9%
- EPS
- -187.1%
- Free Cash Flow
- -313.0%
Profitability
- Gross Margin
- 70.0%
- Operating Margin
- -15.0%
- Net Margin
- -6.5%
- ROE
- -5.2%
- ROIC
- -4.1%
Balance Sheet
- Debt/Equity
- 1.14
- Current Ratio
- 1.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.